Cargando…

Diagnostic performance of the molecular BCR-ABL1 monitoring system may impact on inclusion of CML patients in stopping trials

In chronic myeloid leukemia (CML), the duration of deep molecular response (MR) before treatment cessation (MR(4) or deeper, corresponding to BCR-ABL1 ≤ 0.01% on the International Scale (IS)) is considered as a prognostic factor for treatment free remission in stopping trials. MR level determination...

Descripción completa

Detalles Bibliográficos
Autores principales: Spiess, Birgit, Rinaldetti, Sébastien, Naumann, Nicole, Galuschek, Norbert, Kossak-Roth, Ute, Wuchter, Patrick, Tarnopolscaia, Irina, Rose, Diana, Voskanyan, Astghik, Fabarius, Alice, Hofmann, Wolf-Karsten, Saußele, Susanne, Seifarth, Wolfgang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6428315/
https://www.ncbi.nlm.nih.gov/pubmed/30897165
http://dx.doi.org/10.1371/journal.pone.0214305
_version_ 1783405387094949888
author Spiess, Birgit
Rinaldetti, Sébastien
Naumann, Nicole
Galuschek, Norbert
Kossak-Roth, Ute
Wuchter, Patrick
Tarnopolscaia, Irina
Rose, Diana
Voskanyan, Astghik
Fabarius, Alice
Hofmann, Wolf-Karsten
Saußele, Susanne
Seifarth, Wolfgang
author_facet Spiess, Birgit
Rinaldetti, Sébastien
Naumann, Nicole
Galuschek, Norbert
Kossak-Roth, Ute
Wuchter, Patrick
Tarnopolscaia, Irina
Rose, Diana
Voskanyan, Astghik
Fabarius, Alice
Hofmann, Wolf-Karsten
Saußele, Susanne
Seifarth, Wolfgang
author_sort Spiess, Birgit
collection PubMed
description In chronic myeloid leukemia (CML), the duration of deep molecular response (MR) before treatment cessation (MR(4) or deeper, corresponding to BCR-ABL1 ≤ 0.01% on the International Scale (IS)) is considered as a prognostic factor for treatment free remission in stopping trials. MR level determination is dependent on the sensitivity of the monitoring technique. Here, we compared a newly established TaqMan (TM) and our so far routinely used LightCycler (LC) quantitative reverse transcription (qRT)-PCR systems for their ability to achieve the best possible sensitivity in BCR-ABL1 monitoring. We have comparatively analyzed RNA samples from peripheral blood mononuclear cells of 92 randomly chosen patients with CML resembling major molecular remission (MMR) or better and of 128 CML patients after treatment cessation (EURO-SKI stopping trial). While our LC system utilized ABL1, the TM system is based on GUSB as reference gene. We observed 99% concordance with respect to achievement of MMR. However, we found that 34 of the 92 patients monitored by TM/GUSB were re-classified to the next inferior MR log level, especially when LC/ABL1-based results were borderline to thresholds. Thirteen patients BCR-ABL1 negative in LC/ABL1 became positive after TM/GUSB analysis. In the 128 patients included in the EURO-SKI trial identical molecular findings were achieved for 114 patients. However, 14 patients were re-classified to the next inferior log-level by the TM/GUSB combination. Eight of these patients relapsed after treatment cessation; two of them were re-classified from MR(4) to MMR and therefore did not meet inclusion criteria anymore. In conclusion, we consider both methods as comparable and interchangeable in terms of achievement of MMR and of longitudinal evaluation of clinical courses. However, in LC/ABL1 negative samples, slightly enhanced TM/GUSB sensitivity may lead to inferior classification of clinical samples in the context of TFR.
format Online
Article
Text
id pubmed-6428315
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-64283152019-04-02 Diagnostic performance of the molecular BCR-ABL1 monitoring system may impact on inclusion of CML patients in stopping trials Spiess, Birgit Rinaldetti, Sébastien Naumann, Nicole Galuschek, Norbert Kossak-Roth, Ute Wuchter, Patrick Tarnopolscaia, Irina Rose, Diana Voskanyan, Astghik Fabarius, Alice Hofmann, Wolf-Karsten Saußele, Susanne Seifarth, Wolfgang PLoS One Research Article In chronic myeloid leukemia (CML), the duration of deep molecular response (MR) before treatment cessation (MR(4) or deeper, corresponding to BCR-ABL1 ≤ 0.01% on the International Scale (IS)) is considered as a prognostic factor for treatment free remission in stopping trials. MR level determination is dependent on the sensitivity of the monitoring technique. Here, we compared a newly established TaqMan (TM) and our so far routinely used LightCycler (LC) quantitative reverse transcription (qRT)-PCR systems for their ability to achieve the best possible sensitivity in BCR-ABL1 monitoring. We have comparatively analyzed RNA samples from peripheral blood mononuclear cells of 92 randomly chosen patients with CML resembling major molecular remission (MMR) or better and of 128 CML patients after treatment cessation (EURO-SKI stopping trial). While our LC system utilized ABL1, the TM system is based on GUSB as reference gene. We observed 99% concordance with respect to achievement of MMR. However, we found that 34 of the 92 patients monitored by TM/GUSB were re-classified to the next inferior MR log level, especially when LC/ABL1-based results were borderline to thresholds. Thirteen patients BCR-ABL1 negative in LC/ABL1 became positive after TM/GUSB analysis. In the 128 patients included in the EURO-SKI trial identical molecular findings were achieved for 114 patients. However, 14 patients were re-classified to the next inferior log-level by the TM/GUSB combination. Eight of these patients relapsed after treatment cessation; two of them were re-classified from MR(4) to MMR and therefore did not meet inclusion criteria anymore. In conclusion, we consider both methods as comparable and interchangeable in terms of achievement of MMR and of longitudinal evaluation of clinical courses. However, in LC/ABL1 negative samples, slightly enhanced TM/GUSB sensitivity may lead to inferior classification of clinical samples in the context of TFR. Public Library of Science 2019-03-21 /pmc/articles/PMC6428315/ /pubmed/30897165 http://dx.doi.org/10.1371/journal.pone.0214305 Text en © 2019 Spiess et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Spiess, Birgit
Rinaldetti, Sébastien
Naumann, Nicole
Galuschek, Norbert
Kossak-Roth, Ute
Wuchter, Patrick
Tarnopolscaia, Irina
Rose, Diana
Voskanyan, Astghik
Fabarius, Alice
Hofmann, Wolf-Karsten
Saußele, Susanne
Seifarth, Wolfgang
Diagnostic performance of the molecular BCR-ABL1 monitoring system may impact on inclusion of CML patients in stopping trials
title Diagnostic performance of the molecular BCR-ABL1 monitoring system may impact on inclusion of CML patients in stopping trials
title_full Diagnostic performance of the molecular BCR-ABL1 monitoring system may impact on inclusion of CML patients in stopping trials
title_fullStr Diagnostic performance of the molecular BCR-ABL1 monitoring system may impact on inclusion of CML patients in stopping trials
title_full_unstemmed Diagnostic performance of the molecular BCR-ABL1 monitoring system may impact on inclusion of CML patients in stopping trials
title_short Diagnostic performance of the molecular BCR-ABL1 monitoring system may impact on inclusion of CML patients in stopping trials
title_sort diagnostic performance of the molecular bcr-abl1 monitoring system may impact on inclusion of cml patients in stopping trials
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6428315/
https://www.ncbi.nlm.nih.gov/pubmed/30897165
http://dx.doi.org/10.1371/journal.pone.0214305
work_keys_str_mv AT spiessbirgit diagnosticperformanceofthemolecularbcrabl1monitoringsystemmayimpactoninclusionofcmlpatientsinstoppingtrials
AT rinaldettisebastien diagnosticperformanceofthemolecularbcrabl1monitoringsystemmayimpactoninclusionofcmlpatientsinstoppingtrials
AT naumannnicole diagnosticperformanceofthemolecularbcrabl1monitoringsystemmayimpactoninclusionofcmlpatientsinstoppingtrials
AT galuscheknorbert diagnosticperformanceofthemolecularbcrabl1monitoringsystemmayimpactoninclusionofcmlpatientsinstoppingtrials
AT kossakrothute diagnosticperformanceofthemolecularbcrabl1monitoringsystemmayimpactoninclusionofcmlpatientsinstoppingtrials
AT wuchterpatrick diagnosticperformanceofthemolecularbcrabl1monitoringsystemmayimpactoninclusionofcmlpatientsinstoppingtrials
AT tarnopolscaiairina diagnosticperformanceofthemolecularbcrabl1monitoringsystemmayimpactoninclusionofcmlpatientsinstoppingtrials
AT rosediana diagnosticperformanceofthemolecularbcrabl1monitoringsystemmayimpactoninclusionofcmlpatientsinstoppingtrials
AT voskanyanastghik diagnosticperformanceofthemolecularbcrabl1monitoringsystemmayimpactoninclusionofcmlpatientsinstoppingtrials
AT fabariusalice diagnosticperformanceofthemolecularbcrabl1monitoringsystemmayimpactoninclusionofcmlpatientsinstoppingtrials
AT hofmannwolfkarsten diagnosticperformanceofthemolecularbcrabl1monitoringsystemmayimpactoninclusionofcmlpatientsinstoppingtrials
AT saußelesusanne diagnosticperformanceofthemolecularbcrabl1monitoringsystemmayimpactoninclusionofcmlpatientsinstoppingtrials
AT seifarthwolfgang diagnosticperformanceofthemolecularbcrabl1monitoringsystemmayimpactoninclusionofcmlpatientsinstoppingtrials